Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
FTC tells Novo that Metsera offer may violate US merger law
The proposed purchase of Metsera by Novo "may violate the procedural provisions" of the Hart-Scott-Rodino Act, an FTC official wrote.
Eric Sagonowsky
Nov 5, 2025 4:26pm
Terns mothballs obesity program after phase 2 data fall short
Oct 22, 2025 7:15am
Kailera raises hefty $600M to take Zepbound rival into ph. 3
Oct 14, 2025 9:20am
Skye's CB1 blocker fails to reduce weight in obesity study
Oct 6, 2025 7:55am
Pfizer’s new prize Metsera touts 14% weight loss for GLP-1
Sep 30, 2025 6:40am
Lilly withdraws phase 2 obesity trial before starting enrollment
Sep 25, 2025 8:07am
